Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 4/20 | 0.41 |
| ▸ | HINT1 | P49773 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398833 | 0.84 | HINT1 (0.39) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL6401802 | 0.84 | KDM4E (0.41) | STING1TAS1R3TAS1R1 | |
| SCHEMBL6401495 | 0.76 | LMNA (0.34) | PDE3A | |
| SCHEMBL1582852 | 0.75 | KDM4E (0.43) | STING1HINT1TAS1R3TAS1R1 | |
| SCHEMBL20154781 | 0.74 | HINT1 (0.46) | STING1HINT1HPGDNT5EGSK3A | |
| SCHEMBL16471919 | 0.72 | HINT1 (0.51) | STING1HINT1HPGDNT5EGSK3A | |
| SCHEMBL22577507 | 0.72 | HINT1 (0.51) | STING1HINT1HPGDNT5EGSK3A | |
| SCHEMBL27216242 | 0.72 | HINT1 (0.51) | STING1HINT1HPGDNT5EGSK3A | |
| SCHEMBL25813664 | 0.72 | HINT1 (0.51) | STING1HINT1HPGDNT5EGSK3A | |
| SCHEMBL26808492 | 0.72 | HINT1 (0.51) | STING1HINT1HPGDNT5EGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313752-B1 | METHODS FOR SYNTHESIZING NUCLEOSIDE DERIVATIVES | RIBOZYME PHARM INC (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1313752-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002018405-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | STING1 2435/4885HINT1 151/4885HPGD 1962/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | STING1 2939/4885HINT1 202/4885HPGD 1769/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | STING1 2941/4885HINT1 203/4885HPGD 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.